Department of Surgery, University of São Paulo Hospital das Clínicas, São Paulo, SP, Brazil.
Department of Surgical Oncology, Oncologia D'Or, D'Or Institute for Research and Education (IDOR), São Paulo, SP, Brazil.
Am J Case Rep. 2021 Nov 2;22:e933906. doi: 10.12659/AJCR.933906.
BACKGROUND Peritoneal metastasis is a common progression of abdominal-pelvic cancers, and it is associated with poorer oncological prognosis when compared to other metastasis sites. Its treatment has limited results, mainly because of poor bioavailability of chemotherapy within the abdominal cavity after systemic administration. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) has been proposed as a novel method to deliver chemotherapy directly into the peritoneal surface; it combines the effectiveness and response of an intraperitoneal therapy with benefits of a minimally invasive approach. The laparoscopic capnoperitoneum is used to instill chemotherapy particles in a more efficient way for distribution and penetration when compared to peritoneal lavage. In the present study, we describe the first PIPAC performed in Brazil, according to the standard technique previously described with the Capnopen® nebulizer device, as well as technique details based on our literature review. CASE REPORT A 67-year-old man with pancreatic adenocarcinoma metastatic to the liver at first diagnosis underwent systemic treatment with the FOLFIRINOX protocol. After a major clinical response due to systemic treatment, pancreaticoduodenectomy was performed with resection and radiofrequency ablation of hepatic nodules. After 7 months of follow-up, the patient's condition evolved with symptomatic relapse in the peritoneum. Aiming at better control of this site, multiple PIPAC procedures were performed, showing excellent control of the peritoneal cavity disease. The patient had a sustained response in the peritoneal cavity and showed systemic disease progression 6 months after the first PIPAC procedure, which deceased at 20 months after the first PIPAC procedure and 42 months after the primary diagnosis. CONCLUSIONS This report shows that the PIPAC procedure is reproducible elsewhere, with safety and good functional results.
腹膜转移是腹部-骨盆癌症的常见进展,与其他转移部位相比,其预后较差。其治疗效果有限,主要是因为全身给药后腹腔内化疗的生物利用度较差。加压腹腔内气溶胶化疗(PIPAC)已被提议作为一种将化疗直接递送至腹膜表面的新方法;它将腹腔内治疗的有效性和反应与微创方法的益处相结合。与腹腔灌洗相比,腹腔镜气腹可更有效地输注化疗颗粒,以实现更好的分布和渗透。在本研究中,我们根据先前使用 Capnopen®雾化器设备描述的标准技术,描述了在巴西进行的首例 PIPAC,以及根据我们的文献复习得出的技术细节。
一名 67 岁男性,初诊时患有胰腺腺癌肝转移,接受了 FOLFIRINOX 方案的全身治疗。由于全身治疗引起的主要临床反应,对其进行了胰十二指肠切除术,同时切除和射频消融肝结节。随访 7 个月后,患者病情进展,出现腹膜症状复发。为了更好地控制该部位,进行了多次 PIPAC 手术,显示出对腹膜腔疾病的极好控制。患者在腹膜腔内持续缓解,并在首次 PIPAC 手术后 6 个月出现全身疾病进展,在首次 PIPAC 手术后 20 个月和原发性诊断后 42 个月死亡。
本报告表明,PIPAC 程序在其他地方具有可重复性、安全性和良好的功能结果。